Biohaven Ltd. operates as an independent entity advancing a diverse pipeline of clinical and preclinical therapeutics. The company's research leverages proprietary drug development platforms, including Kv7 ion channel activators, glutamate modulation, and myostatin inhibition. Its clinical programs target a range of conditions such as epilepsy, obsessive-compulsive disorder (OCD), spinocerebellar ataxia, and spinal muscular atrophy. Additionally, Biohaven is developing novel protein degraders for autoimmune diseases and exploring oncology applications. The company retains the non-migraine assets of its former parent company and focuses on addressing diseases with significant unmet medical needs.
